Matthew Plavan
2009 - Cesca Therapeutics
In 2009, Matthew Plavan earned a total compensation of $380K as CFO & EVP, Business Development at Cesca Therapeutics, a 18% decrease compared to previous year.
Compensation breakdown
| Bonus | $30,000 |
|---|---|
| Option Awards | $60,000 |
| Salary | $275,000 |
| Stock Awards | $8,000 |
| Other | $7,000 |
| Total | $380,000 |
Plavan received $275K in salary, accounting for 72% of the total pay in 2009.
Plavan also received $30K in bonus, $60K in option awards, $8K in stock awards and $7K in other compensation.
Rankings
In 2009, Matthew Plavan's compensation ranked 7,703rd out of 9,885 executives tracked by ExecPay. In other words, Plavan earned more than 22.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,703 out of 9,885 | 22nd |
Division Manufacturing | 2,879 out of 3,690 | 22nd |
Major group Measuring, Analyzing, And Controlling Instruments; Photographic, Medical And Optical Goods; Watches And Clocks | 454 out of 607 | 25th |
Industry group Laboratory Apparatus And Analytical, Optical, Measuring, and Controlling Instruments | 159 out of 219 | 27th |
Industry Laboratory Apparatus and Furniture | 3 out of 9 | 67th |
Source: SEC filing on October 25, 2011.
Plavan's colleagues
We found two more compensation records of executives who worked with Matthew Plavan at Cesca Therapeutics in 2009.
News
Arcadia Biosciences CEO Matthew Plavan's 2021 pay jumps 102% to $1.6M
April 19, 2022
Arcadia Biosciences CEO Matthew Plavan's 2020 pay jumps 37% to $794K
April 20, 2021
Arcadia Biosciences CEO Matthew Plavan's 2019 pay stays at $581K
April 17, 2020
Arcadia Biosciences CEO Rajendra Ketkar's 2018 pay jumps 40% to $904K
April 18, 2019